Investor Alert

New York Markets Open in:

Market Pulse Archives

July 16, 2021, 2:35 p.m. EDT

Kadmon's graft-versus-host treatment gets FDA approval

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore


Kadmon Holdings Inc. said Friday that Rezurock, its treatment of chronic graft-versus-host disease (cGVHD) in adjusts and pediatric patients older than 12 was approved by the Food and Drug Administration. The biopharmaceutical company's stock, which has been halted for news until 2:45 p.m. Eastern, was up 7.6% in afternoon trading prior to the halt. Kadmon said it expects Rezurock to be available in the U.S. by late August 2021. "Patients receiving Rezurock reported significant improvements in cGVHD symptoms, showing that not only did treatment result in organ responses, but it also made people feel better," said Stephanie Lee, professor at the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine. "This is so important for a chronic disease with a high symptom burden." The stock has lost 8.0% year to date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +1.99% has gained 15.5%.

+79.11 +1.99%
Volume: 2.40B
May 26, 2022 5:42p

Get news alerts on S&P 500 Index — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.